Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix 3-Month Dosing vs Goserelin in Prostate Cancer
NCT00946920Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jun 2009
- Primary completion
- Mar 2011
- Modality
- Peptides, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of degarelix in prostate cancer (PCa) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoints: Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) and Difference in Cumulative Probability of Testosterone at Castrate Level (≤0.5 ng/mL) Between Degarelix and Goserelin. Started Jun 2009; status: completed.
02
Drugs
degarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00946920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00946920.